» Articles » PMID: 34691016

Serum IgG Anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 in Wuhan, China, and then rapidly spread causing an unprecedented pandemic. A robust serological assay is needed to evaluate vaccine candidates and better understand the epidemiology of coronavirus disease (COVID-19).

Methods: We used the full-length spike (S) protein of SARS-CoV-2 for the development of qualitative and quantitative IgG and IgA anti-S enzyme linked immunosorbent assays (ELISA). A total of 320 sera used for assay development were comprised of pandemic sera from SARS-CoV-2 infected adults (n=51) and pre-pandemic sera (n=269) including sera from endemic human coronavirus infected adults. Reverse cumulative curves and diagnostic test statistics were evaluated to define the optimal serum dilution and OD cutoff value for IgG anti-S and IgA anti-S ELISAs. The IgG and IgA anti-S, and three functional antibodies (ACE-2 receptor blocking antibody, lentipseudovirus-S neutralizing antibody, and SARS-CoV-2 neutralizing antibody) were measured using additional SARS-CoV-2 PCR positive sera (n=76) and surveillance sera (n=25). Lastly, the IgG and IgA anti-S levels were compared in different demographic groups.

Results: The optimal serum dilution for the qualitative IgG anti-S ELISA was at 1:1024 yielding a 99.6% specificity, 92.2% sensitivity, 92.9% positive predictive value (PPV), and 99.6% negative predictive value (NPV) at a SARS-CoV-2 seroprevalence of 5%. The optimal serum dilution for the qualitative IgA anti-S ELISA was at 1:128 yielding a 98.9% specificity, 76.5% sensitivity, 78.3% PPV, and 98.8% NPV at the same seroprevalence. Significant correlations were demonstrated between the IgG and IgA (r=0.833 for concentrations, r=0.840 for titers) as well as between IgG and three functional antibodies (r=0.811-0.924 for concentrations, r=0.795-0.917 for titers). The IgG and IgA anti-S levels were significantly higher in males than females (p<0.05), and in adults with moderate/severe symptoms than in adults with mild/moderate symptoms (p<0.001).

Conclusion: We developed a highly specific and sensitive IgG anti-S ELISA assay to SARS-CoV-2 using full length S protein. The IgG anti-S antibody level was strongly associated with IgA and functional antibody levels in adults with SARS-CoV-2 infection. Gender and disease severity, rather than age, play an important role in antibody levels.

Citing Articles

Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins.

Thimmiraju S, Villar M, Kimata J, Strych U, Bottazzi M, Hotez P Viruses. 2024; 16(9.

PMID: 39339968 PMC: 11437443. DOI: 10.3390/v16091492.


The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.

Noviello M, De Lorenzo R, Chimienti R, Maugeri N, De Lalla C, Siracusano G Front Immunol. 2024; 15:1381091.

PMID: 39136010 PMC: 11317765. DOI: 10.3389/fimmu.2024.1381091.


Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.

Liu Y, Guo Y, Zhan H, Liu X, Li X, Cui J BMC Infect Dis. 2024; 24(1):809.

PMID: 39123106 PMC: 11316362. DOI: 10.1186/s12879-024-09652-y.


Development of a colloidal gold-based immunochromatographic assay for rapid detection of nasal mucosal secretory IgA against SARS-CoV-2.

Sun B, Chen Z, Feng B, Chen S, Feng S, Wang Q Front Microbiol. 2024; 15:1386891.

PMID: 38881666 PMC: 11177785. DOI: 10.3389/fmicb.2024.1386891.


The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China.

Chu J, Dai Q, Dong C, Kong X, Tian H, Li C Front Public Health. 2024; 12:1364048.

PMID: 38873290 PMC: 11169644. DOI: 10.3389/fpubh.2024.1364048.


References
1.
Theel E, Harring J, Hilgart H, Granger D . Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J Clin Microbiol. 2020; 58(8). PMC: 7383546. DOI: 10.1128/JCM.01243-20. View

2.
Shammi M, Bodrud-Doza M, Islam A, Rahman M . COVID-19 pandemic, socioeconomic crisis and human stress in resource-limited settings: A case from Bangladesh. Heliyon. 2020; 6(5):e04063. PMC: 7242967. DOI: 10.1016/j.heliyon.2020.e04063. View

3.
Benner S, Patel E, Laeyendecker O, Pekosz A, Littlefield K, Eby Y . SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J Infect Dis. 2020; 222(12):1974-1984. PMC: 7499592. DOI: 10.1093/infdis/jiaa581. View

4.
Nuccetelli M, Pieri M, Gisone F, Bernardini S . Combined anti-SARS-CoV-2 IgA, IgG, and IgM Detection as a Better Strategy to Prevent Second Infection Spreading Waves. Immunol Invest. 2020; 51(2):233-245. PMC: 7544959. DOI: 10.1080/08820139.2020.1823407. View

5.
Letko M, Marzi A, Munster V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4):562-569. PMC: 7095430. DOI: 10.1038/s41564-020-0688-y. View